Bruker Corporation (Nasdaq: BRKR), a US-based manufacturer of scientific instruments for molecular and materials research, announced on Monday that it showcased significant advancements in 4D-Proteomics with improved mass spectrometry tools and software aimed at deepening biological insights at the 21st Annual US HUPO Conference
The company introduced a new AIP (Accelerated Ion Processing) feature on the timsTOF Ultra 2 mass spectrometer, improving peptide and protein identification for single-cell proteomics. The technology shows a 15% increase in protein IDs and 20% improvement in peptide IDs, enhancing sequence coverage. The company plans to launch this feature at ASMS 2025 with field upgradability.
Additionally, Bruker unveiled DeutEx, a software for hydrogen-deuterium exchange mass spectrometry (HDX-MS), now integrated into its proteomics ecosystem. Developed by Dr Petr Novák of the Czech Academy of Sciences, DeutEx aids in studying structural and dynamic properties of proteins, further supporting biopharma research.
Bruker also highlighted OmniScape 2025b, which offers a 10x increase in de novo sequencing performance and advanced integration for top-down proteomics. Updates to ProteoScape V.2025c and GlycoScape now enable automated, high-throughput glycoform profiling, enhancing glycoproteomics analysis with improved performance and custom modification options.
Finally, Bruker introduced TwinScape, a cloud-based AI-enabled software that provides real-time quality monitoring for hundreds of customer systems, including nanoElute LCs and the timsTOF series.
These innovations strengthen Bruker's position as a leader in proteomics, supporting next-generation scientific discovery across biopharma and life sciences.
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention
Alume Biosciences names new chief commercial officer
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss